Using pembrolizumab to treat advanced squamous cell carcinoma before surgery

Who could benefit from this research

What this research studies

This research investigates the use of pembrolizumab, an immunotherapy drug, as a neoadjuvant treatment for patients with locally advanced squamous cell carcinoma (SCC) who have not previously received PD-1 inhibitors. The trial aims to assess the effectiveness of this treatment in shrinking tumors before surgical removal. Patients will receive pembrolizumab and be monitored for their response to the therapy, which may include imaging and clinical evaluations. The goal is to improve surgical outcomes and overall patient prognosis.

Why it matters

Where this research is happening

• University of Pittsburgh at Pittsburgh
  Pittsburgh, United States Active

Researchers

• Principal investigator: Zarour, Hassane M — University of Pittsburgh at Pittsburgh
• Study coordinator: Zarour, Hassane M

Related research

Other NIH-funded projects on the same topics.

• Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe

  A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.

  NIH research H. Lee Moffitt Cancer Ctr & Res Inst · Tampa, United States · NIH-11625534

• Oral cancer recurrence predictor using tumor microbes and gene activity

  This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11591548

• Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer

  A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11505841

• Targeting PIPKIγi5 to boost immune responses against head and neck cancer

  A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.

  NIH research Virginia Commonwealth University · Richmond, United States · NIH-11449300

• Targeted approaches for lung squamous cell carcinoma with key gene changes

  A study at a major university is exploring new targets in lung squamous cell carcinoma to help people with this cancer find better treatments.

  NIH research University of Pittsburgh at Pittsburgh · Pittsburgh, United States · NIH-11449092

• Baculovirus-based therapy to treat head and neck cancer with a gentle, minimally invasive approach

  A new, minimally invasive approach using baculovirus-delivered CRISPR gene editing aims to treat head and neck squamous cell carcinoma while aiming to preserve essential tissues.

  NIH research University of Kentucky · Lexington, United States · NIH-11445557

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.